PDCD1 and cancer: At present, numerous anti-PD-1 antibodies (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and anti-PD-L1 antibodies (atezolizumab, durvalumab, and avelumab) have been approved for various types of cancers (49) (Table 1).